CAR T-Cell Therapy: Putting the Immune System to Work against Leukemia
What is CAR T-Cell Therapy?
Chimeric antigen receptor T-cell (CAR T-cell) therapy is a recently developed strategy for the treatment of leukemia, the most commonly found malignancy in children. Sheba Medical Center has achieved successful results with this cutting-edge therapy.
The number of adults who have undergone this therapy CAR T-cell therapy at Sheba:
How Does The Therapy Work?
An amount of blood is taken from the patient and the T-cells, a type of immune cell, are separated out from the rest of the blood in a special laboratory. The T-cells are then genetically engineered to cause them to produce chimeric antigen receptors (CARs). The CARs will allow the T-cells to recognize tumor cells, targeting and destroying the tumor.
In effect, the CAR T-cell therapy process turns the patient’s own T-cells into hunter-killers of cancer.
The engineered T-cells are given some time to multiply in the laboratory and then injected back into the patient. The patient receives chemotherapy while the cells are growing in the lab. The chemotherapy will suppress the patient’s immune system, allowing the CAR T-cells to perform better once they’re injected.
The entire process takes about 10 days, but patients remain in the hospital for a minimum of 2 weeks for monitoring of toxicities.
This observation period may be longer.
What are the Possible Side Effects from CAR T-Cell Therapy?
CAR T-cells are associated with significant but reversible side effects in 40-60% of patients treated.
These include a flu-like syndrome with fever and shortness of breath. This syndrome may lead to low blood pressure, chills, and more. Neurologic side effects, like a headache and seizures, have been reported. All these effects are reversible, but may be significant and require treatment in the ICU.
Who is a Candidate for CAR T-Cell Therapy?
The therapy is only provided to patients who have undergone at least two previous leukemia treatments.
CAR T-cell treatment has been quite successful in younger patients. For example, young children have experienced a total recovery rate of about 85-90%. Approximately 80% of teenagers receiving the treatment have made a complete recovery from their leukemia. A success rate of about 70% has been achieved in the total patient population.
Sheba and other medical centers located in the US are continually striving to improve these success rates through constant advanced research.
Sheba is excited to announce that it now offers the innovative CAR T-cell therapy for patients with Multiple Myeloma and is the first medical center in the world to pioneer its application for Acute Myelogenous Leukemia (AML) with 8:21 translocation and CD19 expression as part of a clinical study.
We also offer a full diagnostic procedure to determine whether this treatment is a suitable option for a patient.
Dr. Ofer Margalit completed M.D. degree, as part of an M.D.-
Specializing in breast cancer treatment, Dr. Tal Shapira-Rot
Dr. Meital Levartovsky is a senior oncologist in GU Unit at
Dr. Moran Gadot is a senior oncologist in GU unit at the Can
Request a consultation
Sheba Medical Center provides innovative, personalized medical care to patients from around the world. We are the largest, most comprehensive hospital in the Middle East and dedicated to providing advanced and compassionate medicine for everyone.
We welcome all cases, including the rarest and the most challenging. Our medical teams collaborate to provide the best possible health outcomes. From your initial inquiry through the long-term follow-up care, we are here for you.
Request a consultation and a Sheba Case Manager will contact you shortly: